## Table of Contents

- **Header** 1
- **Abstract** 1
- **Plain Language Summary** 2
- **Background** 2
- **Objectives** 2
- **Methods** 3
- **Results** 5
- **Discussion** 9
- **Authors’ Conclusions** 10
- **Acknowledgements** 10
- **References** 13
- **Characteristics of Studies** 22
- **Data and Analyses** 29
  - Analysis 1.1. Comparison 1 Multivitamin supplement versus placebo, Outcome 1 Distance visual acuity: mean 23
  - Analysis 2.1. Comparison 2 Zinc versus placebo, Outcome 1 Distance visual acuity: loss of 3 or more lines 23
  - Analysis 2.2. Comparison 2 Zinc versus placebo, Outcome 2 Distance visual acuity: mean 24
  - Analysis 2.3. Comparison 2 Zinc versus placebo, Outcome 3 Progression AMD: dichotomous 25
  - Analysis 3.1. Comparison 3 Any multivitamin or single component antioxidant supplement versus placebo, Outcome 1 Distance visual acuity: loss of 3 or more lines 25
  - Analysis 3.2. Comparison 3 Any multivitamin or single component antioxidant supplement versus placebo, Outcome 2 Distance visual acuity: mean 26
  - Analysis 3.3. Comparison 3 Any multivitamin or single component antioxidant supplement versus placebo, Outcome 3 Progression AMD: dichotomous 27
- **Additional Tables** 27
- **Appendices** 29
- **What’s New** 33
- **History** 34
- **Declarations of Interest** 34
- **Sources of Support** 34
- **Notes** 35
- **Index Terms** 35
Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration

Jennifer R Evans

1Cochrane Eyes and Vision Group, ICEH, London School of Hygiene & Tropical Medicine, London, UK

Contact address: Jennifer R Evans, Cochrane Eyes and Vision Group, ICEH, London School of Hygiene & Tropical Medicine, Keppel Street, London, WC1E 7HT, UK. jennifer.evans@lshtm.ac.uk.

Editorial group: Cochrane Eyes and Vision Group.

Publication status and date: Edited (no change to conclusions), published in Issue 1, 2009.

Review content assessed as up-to-date: 1 August 2007.

Citation: Evans JR. Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration. Cochrane Database of Systematic Reviews 2006, Issue 2. Art. No.: CD000254. DOI: 10.1002/14651858.CD000254.pub2.

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

ABSTRACT

Background

It has been proposed that antioxidants may prevent cellular damage in the retina by reacting with free radicals that are produced in the process of light absorption.

Objectives

The objective of this review was to assess the effects of antioxidant vitamin or mineral supplementation on the progression of age-related macular degeneration (AMD).

Search methods

We searched the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library (2007, Issue 3); MEDLINE (1966 to August 2007); EMBASE (1980 to August 2007); NRR (2007, Issue 3); AMED (1985 to January 2006); PubMed (24 January 2006 covering last 60 days) and SIGLE (1980 to March 2005), reference lists of identified reports and the Science Citation Index. We contacted investigators and experts in the field for details of unpublished studies.

Selection criteria

We included randomised trials comparing antioxidant vitamin or mineral supplementation (alone or in combination) to a control intervention in people with AMD.

Data collection and analysis

The author extracted data and assessed trial quality. Where appropriate, data were pooled using a random-effects model unless three or fewer trials were available in which case a fixed-effects model was used.

Main results

Nine trials were included in this review. The majority of people were randomised in one trial (AREDS in the USA) that found a beneficial effect of antioxidant (beta-carotene, vitamin C and vitamin E) and zinc supplementation on progression to advanced AMD (adjusted odds ratio 0.68, 99% confidence interval 0.49 to 0.93). People taking supplements were less likely to lose 15 or more letters of visual acuity (adjusted odds ratio 0.77, 99% confidence interval 0.58 to 1.03). Hospitalisation for genito-urinary problems was more common in people taking zinc and yellowing of skin was more common in people taking antioxidants. The other trials were, in general, small and the results were inconsistent.
Authors’ conclusions

The evidence as to the effectiveness of antioxidant vitamin and mineral supplementation in halting the progression of AMD comes mainly from one large trial in the USA. The generalisability of these findings to other populations with different nutritional status is not known. Further large, well-conducted randomised controlled trials in other populations are required. Long-term harm from supplementation cannot be ruled out. Beta-carotene has been found to increase the risk of lung cancer in smokers; vitamin E has been associated with an increased risk of heart failure in people with vascular disease or diabetes.

Plain Language Summary

Antioxidant vitamins and mineral supplements to slow down the progression of age-related macular degeneration

Age-related macular degeneration (AMD) is a condition affecting the central area of the retina (back of the eye). The retina can deteriorate with age and some people get lesions that can lead to loss of central vision. It has been suggested that progression of the disease may be slowed down in people who eat a diet rich in antioxidant vitamins (carotenoids, vitamins C and E) or minerals (selenium and zinc). The author identified nine randomised controlled trials; four trials based in the USA, four in Australia, Austria, Switzerland and the UK and one in China. The review of trials found that supplementation with antioxidants and zinc may be of modest benefit in people with AMD. Long-term harm from these supplements cannot be ruled out. Large well-conducted trials in a range of populations and with different nutritional status are required.

Background

Introduction

Age-related macular degeneration (AMD) is a disease affecting the central area of the retina (macula). In the early stages of the disease lipid material accumulates in deposits underneath the retinal pigment epithelium. These deposits are known as drusen and can be seen as pale yellow spots on the retina. The pigment of the retinal pigment epithelium may become disturbed with areas of hyperpigmentation and hypopigmentation. In the later stages of the disease the retinal pigment epithelium may atrophy completely. This loss can occur in small focal areas or can be widespread (geographic). In some cases new blood vessels grow under the retinal pigment epithelium and occasionally into the subretinal space (exudative or neovascular AMD). Haemorrhage can occur which often results in increased scarring of the retina.

Presentation and epidemiology

The early stages of the disease are in general asymptomatic. In the later stages there may be considerable distortion of vision and complete loss of visual function, particularly in the central area of vision. Population-based studies suggest that in people 75 years and older, approximately 30% have early signs of the disease and 7% have late-stage disease (Klein 1992). It is the most common cause of blindness and visual impairment in industrialised countries. In the UK, for example, over 30,000 people annually are registered as blind or partially sighted, half of whom have lost their vision due to macular degeneration (Evans 1996).

Treatment options

Currently there is no treatment that can restore vision in AMD. Photoreceptors in the retina are subject to oxidative stress throughout life due to combined exposures to light and oxygen. It has been proposed that antioxidants may prevent cellular damage in the retina by limiting the damaging effects of free radicals produced in the process of light absorption (for a review see Christen 1996). Antioxidant vitamin and mineral supplements are increasingly being marketed for use in age-related eye disease, including AMD.

Objectives

The objective of this review was to assess the effects of antioxidant vitamin or mineral supplementation, alone or in combination, on the progression of AMD.
METHODS

Criteria for considering studies for this review

Types of studies
This review included randomised controlled trials.

Types of participants
Participants in the trials were people with AMD in one or both eyes.

Types of interventions
We included trials in which antioxidant vitamin or mineral supplementation, alone or in combination, was compared to placebo or no intervention. Antioxidants were defined as any vitamin or mineral which is known to have antioxidant properties in vivo or which is known to be an important component of an antioxidant enzyme present in the retina. The following were considered: vitamin C, vitamin E, carotenoids, selenium and zinc.

Types of outcome measures

Primary outcomes
The primary outcome for this review was vision. As one of the consequences of AMD is a progressive loss of vision the preferred outcome was dichotomous (loss of three or more lines of visual acuity) which, if measured on a logMAR chart, reflects a doubling of the visual angle. This is a meaningful clinical change for patients. However, some studies report vision as a continuous measure so I also looked at the mean difference. If there were studies that used different ways of measuring vision (for example, some may report vision at the end of the study, some may report change) I calculated a standardised mean difference. Snellen values were converted to logMAR to ensure that there was consistency in the direction of effect (higher Snellen values reflect better vision, higher logMAR values reflect poorer vision).

Secondary outcomes
Secondary outcomes included progression of the disease. There are several ways of measuring this. I decided to use progression as defined by the study investigators as the outcome. This was usually reported as a dichotomous outcome.

Assessment of methodological quality
The author assessed trial quality according to methods set out in Section 6 of the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2006). Five parameters were considered: allocation concealment, method of allocation to treatment, documentation of exclusions, masking of outcome assessment and completeness of follow up.

Electronic searches
We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (which contains the Cochrane Eyes and Vision Group Trials Register) in The Cochrane Library, MEDLINE, EMBASE, National Research Register (NRR), PubMed, Allied & Complementary Medicine (AMED), SIGLE. The searches in The Cochrane Library, MEDLINE, EMBASE and NRR were last updated on 2 August 2007. There were no language or date restrictions in the searches.

Searching other resources
We searched the reference lists of identified trial reports to find additional trials. The Science Citation Index was used to find studies that cite the identified trials. We contacted investigators of included studies to identify additional published and unpublished studies.

Data collection and analysis

Selection of trials
The author assessed the titles and abstracts of all reports of trials identified by the electronic searching. The full texts of possibly relevant trials were obtained. Relevant studies were selected according to the definitions in the 'Criteria for considering studies for this review'.

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Data collection

The author extracted data using a standardised form developed by the Cochrane Eyes and Vision Group. These data were sent for verification to the trial investigators of all studies included in the review.

Analysis strategy

Previous versions of this review did not include statistical analyses because only a small number of trials were identified and variable methods of collecting and presenting outcome data were used. More trials in this area have become available and new developments in statistical software and Cochrane guidelines mean that the analysis section was substantially revised for later versions of the review.

The following plan was set out (and reviewed by the statistical editorial team) in September 2005, before re-doing the analyses. It should be noted that this plan was developed with knowledge of the trials and the results included in previous versions of this review. However, every effort has been taken to base judgements as to the analysis on methodological grounds without reference to the results of the individual trials.

Comparisons

The overall objective of the review was to assess the impact of antioxidant vitamin and mineral supplements on the progression of AMD. Trials in this area fall into two broad categories: those evaluating a single vitamin or mineral (for example, vitamin E or zinc) and those investigating a broad spectrum formulation (for example, Ocuguard). The following comparisons were considered in this review.

(1) Broad-spectrum formulation versus placebo. Within this category fall all the broad-spectrum formulations which include one or more antioxidant vitamins or minerals.

(2) Single-component formulations versus placebo. Currently only vitamin E, zinc and lutein have been studied as single formulations, however, it is likely that in future other trials will be published which investigate individual components.

(3) All trials of broad-spectrum or single component studies together.

The traditional study design method in this area is parallel group randomised controlled trials. Cluster randomised trials are unlikely but would still be considered. Cross-over studies would not be appropriate in this area because of the uncertain and complex natural history of AMD. If such studies are reported the first phase only would be used.

Some studies report findings on right eyes and left eyes separately. As there is no hypothesis that the effect of antioxidant supplements should differ according to eye, I have made the a priori decision to consider right eyes only.

Which measure of effect?

In general the risk ratio is to be preferred when the proportion of the control group experiencing the event of interest is greater than 10%. However, in this particular case the main trial from which over 80% of the information on this topic is available reported odds ratios and their confidence intervals only (derived from repeated measures logistic regression). For this reason, I have analysed the data using the generic inverse variance method with the main effect measure being the odds ratio. The standard error was calculated from the confidence interval from each study. In discussion of the results of the review, where possible, I have converted the pooled odds ratio back to the risk ratio to ensure that any estimates of effect are not exaggerated. The risk ratio was calculated using the following formula: $RR = OR / (1-P_0) \times (P_0 \times OR)$ where $P_0$ is the incidence of the outcome of interest in the control group.

How will the decision be made as to whether it is appropriate to pool data?

I considered how similar the trials were and looked at the forest plot to see whether the effect measures for the different studies were in the same direction and of a similar order of effect. I then examined the $I^2$ value. A value of 50% or more was taken to indicate considerable inconsistency of results such that a pooled result may be inaccurate and should not be reported.

Which model will I use?

I used a random-effects model, unless there were three or fewer trials in which case I used a fixed-effect model. I compared fixed and random-effects models to see how robust the result was.

How will clinical and methodological diversity be addressed? How will these be incorporated into the analysis strategy?

The main clinical diversity was with respect to the type of supplement. This is incorporated into the analysis strategy by considering the formulations by type (see Comparisons 1 and 2). Again with methodological diversity, the type of study design was fairly standard and straightforward, however, the methodological quality of the studies was reported and used to interpret the results (see below).

How will the quality of included studies be addressed in the analysis section?

Currently there are not enough published studies to enable sensitivity analysis. However, should enough studies become available in the future, the proposal would be to repeat the analysis including only high quality studies. All studies included in the review were randomised controlled trials. The main quality attributes in this area are: (i) whether or not the randomisation was properly concealed, (ii) whether or not the participants were masked, (iii) whether or not the outcome assessment was masked, and (iv) extent of follow up in the study groups. In practice, most studies compare the supplements versus placebo and report that the masking was adequate, that is that the tablets were similar etc. It is likely that the main quality attributes that may differ between studies will be allocation concealment and follow up.

Pre-specify characteristics of the studies that may be examined as potential causes of heterogeneity
Currently there are not enough studies to perform any sub-group analyses and these are not proposed for this version of the review. One characteristic that may be important is the type of AMD or severity of AMD. Subgroup analyses on type or severity of AMD may be considered in future.

**How will missing data be handled?**

It was proposed to do an available case analysis. Currently only one study (Stur 1996) specifically excluded people who experienced a neovascular event (one component of late stage AMD) from the analyses. The published report did not give enough information to include these people in the analyses. If missing data should prove to be a problem in the constituent studies, that is if follow up was less than 80% for trials contributing more than 50% of the data for the analysis, I will do a sensitivity analysis considering outcome in the people lost to follow up as either ‘all OK’ or ‘all not OK’ to see the range within which the true result might lie. However, currently this was not considered to necessary as the largest trial in the area had follow up of nearly 98%.

**Whether or how evidence of possible publication or reporting biases will be sought**

Currently there are not enough studies to examine this formally, however, I reviewed the forest plots to see if there was any sign that this might be happening i.e. whether smaller studies were reporting larger effects.

**RESULTS**

**Description of studies**

See: Characteristics of included studies; Characteristics of excluded studies.

**Results of the search**

The original electronic searches identified 577 reports of possible AMD trials of which five reports (four trials) were of antioxidant interventions (AMDSG; Kaiser 1995; Newsome 1988; Stur 1996). These four trials met the inclusion criteria for this review. Contact with a trial author identified an additional trial of zinc supplementation that has been published in abstract form only (Holz 1993).

In October 2001, the result of the Age-Related Eye Disease Study (AREDS) was published. The reference list of this study report identified that the Vitamin E, Cataract and Age-related Maculopathy Study (VECAT) had been published in abstract form only.

Searching the reference lists of trial reports located one further possible relevant trial (Vannas 1958). This study was not included in the review because there was no evidence from the report that the comparison groups (heparin, vitamin A and E, Hydergin therapy and placebo) were randomly allocated or that the allocation was concealed in any way. As the trial was conducted in 1958, no further attempt was made to clarify this.

A trial of zinc supplementation (30 mg daily) of people with neovascular AMD in one eye and drusen in the other (n = 170) has been conducted and is as yet unpublished (France 1998). This trial is listed as 'Awaiting assessment' in this review.

Searches were first performed in August 1997 and repeated in October 1998, December 1999, September 2000, November 2001 and May 2005. Two further trials were identified: Veterans LAST study and a trial published in Chinese which is currently awaiting assessment (Wang 2004). The searches were updated in January 2006 and August 2007 but no new trials were identified.

**Included studies**

Below is a summary of the eight trials included in this review. See ‘Characteristics of included studies’ for detailed information about the trials.

**Types of participants**

The average age of people participating in the trials was 70 years. Slightly more women than men were recruited with the exception of AMDSG and Veterans LAST study where predominantly men were enrolled. In AREDS it was noted that people taking part in the trial were relatively well-nourished compared to the general population.

People taking part in the trials were identified by referral from local ophthalmologists (Kaiser 1995; Newsome 1988), from people attending Department of Veterans Medical Centers (AMDSG; Veterans LAST study), from retinal specialty clinics and general population volunteers (AREDS), from an eye outpatient clinic (Stur 1996; Wang 2004) and from the general population (VECAT).

The trials enrolled groups of people with AMD at different stages of the disease: AMDSG and Veterans LAST study considered people with early macular degeneration only; Newsome 1988 examined people with both early and late-stage disease; Stur 1996 enrolled people with late-stage disease in one eye; Kaiser 1995 recruited only people with geographic AMD. In AREDS participants had a range of disease from mild or borderline features to advanced AMD which was defined as geographic atrophy involving the centre of the macula or features of choroidal neovascularisation. The majority of the participants in VECAT had no or mild age-related maculopathy.

**Types of intervention**

Three trials compared zinc sulfate 200 mg daily versus placebo (Holz 1993; Newsome 1988; Stur 1996). Two trials compared a broad-spectrum antioxidant complex versus placebo (AMDSG -
Ocuguard; Kaiser 1995 - Visaline). VECAT compared vitamin E (500 international units (IU) daily) with placebo. In AREDS a 2x2 factorial design was used. Participants were randomised into four groups: placebo, zinc alone (80 mg daily), antioxidants (vitamin C 500 mg, vitamin E 400 IU and beta-carotene 15 mg) alone and zinc plus antioxidants. In AREDS 67% of participants took other multivitamin supplements to recommended daily allowance levels (Centrum). The Veterans LAST study compared lutein 10 mg daily to lutein plus a broad-spectrum antioxidant (OcuPower). The duration of supplementation in these trials ranged from six months to seven years. The Chinese trial studied zinc oxide (80 mg daily), vitamin C (dose unknown) and vitamin E (dose unknown).

Types of outcome measures

All the trials used different outcome measures for visual function and progression of disease. AMDSG and Veterans LAST study measured vision using Snellen acuity and converted the score into logMAR units. Newsome 1988 and AREDS used the visual acuity chart developed as part of the Early Treatment of Diabetic Retinopathy Study (ETDRS 1980). Stur 1996 and VECAT used Bailey-Lovie Charts #4 and #5 (National Vision Research Institute, Australia). Some studies have presented vision as a continuous outcome (AMDSG: Kaiser 1995; Stur 1996), others have used a cut-off of loss of 10 (Newsome 1988) or 15 letters of acuity (AREDS). A loss of 15 letters of acuity is equivalent to a loss of three lines of vision read on the chart and is the same as experiencing a doubling of the visual angle.

In most studies disease progression was assessed by grading stereoscopic colour photographs of the retina. Stur 1996 used the Wisconsin Age-Related Maculopathy Grading System (Klein 1991); AMDSG used the grading system developed as part of the Chesapeake Bay Waterman Study (Bressler 1989); VECAT used the International Grading System (ARMDSG 1995); AREDS adapted the Wisconsin system. The Wisconsin, AREDS and International Systems are closely related; the latter was published after the two former systems were in use. All these grading systems involve classification into categories according to the number and type of drusen, pigmented abnormalities and presence of geographic atrophy or neovascularisation. In AMDSG and Stur 1996 these categories were accorded a score which was analysed as a continuous measure. Newsome 1988 recorded the number of cases of increased drusen, pigment abnormalities and atrophy. Kaiser 1995 did not include any measures of progression of AMD.

AREDS reported data for three categories of participant: (i) mild or borderline AMD features (n = 1063); (ii) AMD but not advanced AMD (n = 1621) and (iii) advanced AMD or reduced visual acuity due to AMD in one eye (n = 956). Advanced AMD was defined as signs of geographic atrophy involving the centre of the macula or signs of choroidal neovascularisation (defined as the presence of fluid, blood or fibrovascular tissue under the retina or retinal pigment epithelium).

The study followed up 90% of the cohort by the end of five years; the mean follow-up time was 6.3 years. On the basis of having missed the last two consecutive study visits, 2.4% were defined as lost to follow up. In the borderline AMD group, 1.3% progressed to advanced AMD by five years (15 AMD events); in the advanced AMD category, 43% progressed to advanced AMD (in the other eye) by five years and 18% progressed in the intermediate group. At five year follow up 71% of participants were taking 75% or more of their tablets. The investigators found that individuals with outcomes such as signs of advanced AMD and visual acuity loss of 15 or more letters could recover later on. Approximately 8% of the identified cases of advanced AMD, based on central grading of colour stereo photographs, apparently recovered as the AMD lesions were not seen on subsequent yearly photographs. The report did not distinguish between grading errors and verified disappearance of lesion. For this reason they used repeated measures logistic regression which counts each event but also allows for the fact that the event could ‘recover’. Outcomes were not clearly defined for the Chinese trials (Wang 2004).

Risk of bias in included studies

Most of the trials were small. The number of participants for which data were analysed ranged from 20 to 151. In only one trial (Stur 1996) was an a priori sample size estimate reported but the trial was terminated early when follow up of the first 40 patients showed no detectable trend. The more recent trials, AREDS and VECAT, were larger at 3640 and 1204 participants respectively and were based on prior sample size calculations. In the case of VECAT, however, sample size was based on estimated prevalence and incidence of cataract rather than age-related maculopathy. In addition, most of the 1204 participants did not have signs of AMD at the beginning of the study and were, therefore, also included in the related Cochrane review on prevention of AMD (Evans 2008).

In most trials randomisation appeared to have been executed properly, that is, an unpredictable sequence of treatment allocation was concealed adequately from people recruiting participants into the trial. As Holz 1993 has only been published in abstract form to date the details of randomisation were not clear. In AMDSG more people in the placebo group withdrew (six) compared to the treatment group (one). The description of the tablets cannot exclude the possibility that there were detectable differences between treatment and placebo that may mean that some participants in the study were unmasked. In AREDS four people were documented as being unmasked to study group. More people in the antioxidant group (8.3%) reported changes in skin colour (yellowing) than in the placebo group (6.0%, P < 0.01) and more people in the zinc groups reported difficulty swallowing the study tablets (17.8% versus 15.3%, P = 0.04). However, there was little evi-
dence of unmasking when at the end of the study participants were asked to guess their treatment assignment. The percentages of participants who guessed correctly, by treatment assignment, were: placebo 17%, antioxidants alone 16%; zinc alone 18%; and antioxidants plus zinc 16%.

In the Veterans LAST study the tablets were apparently identical in appearance but it was not clear whether taste or systemic effects differed between the different groups.

In Stur 1996 analysis of the main outcome measures (visual function and progression of disease) was not done on a strictly intention-to-treat basis as anyone experiencing the endpoint of late-stage AMD (neovascularisation) was withdrawn from the study. Contact with the trial investigator revealed that all of these participants ended up with visual acuity of 20/200 or less and that these participants were excluded because the investigators wished to detect functional changes caused by degeneration of the retinal pigment epithelium and the sensory retina and not vision losses caused by choroidal neovascularisation.

There was not enough information available for the trial conducted in China (Wang 2004) to assess study quality (see ‘Characteristics of included studies’ table).

Effects of interventions

Table 1 provides more information on the outcomes and follow-up times relating to the data included in these analyses.

Comparison 1: multivitamin supplement versus placebo

These analyses were restricted to trials of multivitamin and mineral supplements: AREDS (vitamins C, E, beta-carotene and zinc), AMDSG (Ocuguard), Kaiser 1995 (Visaline) and Veterans LAST study (Ocupower). See ‘Characteristics of included studies’ for details of vitamins and minerals included in Ocuguard, Visaline and Ocupower.

Outcome 1 distance visual acuity: loss of three or more lines

Only AREDS reported visual acuity data in a dichotomous format. People who received antioxidant vitamins plus zinc were less likely to lose 15 or more letters of visual acuity. The odds ratio (OR) adjusted age, sex, race, AMD category and baseline smoking status was 0.77, 95% CI 0.62 to 0.96.

Outcome 2 distance visual acuity: mean

Trials reporting visual acuity in continuous format were smaller and had shorter treatment and follow-up durations (6 months to 18 months) (AMDSG; Kaiser 1995; Veterans LAST study). A total of 69 people were randomised to treatment and 62 to placebo in pooled analyses of all three trials. The results of these trials were consistent \( I^2 = 0 \). Little effect of treatment on visual acuity was seen from these analyses. The pooled standardised mean difference was 0.16 (95% CI -0.19 to 0.51) (Analysis 1.1).

Outcome 3 progression AMD: dichotomous

Only the AREDS trial contributed to this outcome. People taking antioxidant vitamins plus zinc were less likely to progress to advanced AMD. The OR adjusted for age, sex, race, AMD category and baseline smoking status was 0.68, 95% CI 0.53 to 0.87.

Outcome 4 progression AMD: continuous

Only one trial reported the progression of AMD in a continuous format (AMDSG), with 25 people randomised to treatment and 24 to control. There was little evidence of any effect of treatment at 18 months (mean difference -0.06, 95% CI -0.62 to 0.50). The power of the study was low.

Comparison 2: zinc versus placebo

Four trials have investigated the effect of zinc supplementation (AREDS; Holz 1993 (published in abstract form only); Newsome 1988; Stur 1996). In addition there is one unpublished study for which we have no data (France 1998).

Outcome 1, distance visual acuity: loss of three or more lines

Two trials reported visual acuity data in this format (AREDS; Newsome 1988). The pooled analyses include a total of 984 people randomised to zinc supplementation and 974 to placebo. The trials were consistent \( I^2 = 0 \). There was a modest beneficial effect of treatment on visual acuity (pooled OR 0.81, 95% CI 0.66 to 0.99). (Analysis 2.1)

Outcome 2 distance visual acuity: mean

Two trials provided data for this outcome (Newsome 1988; Stur 1996). A total of 77 people were randomised to zinc supplementation and 78 to placebo in these two trials which had a maximum treatment and follow-up duration of 24 months. The results of these trials were less consistent, \( I^2 = 56.6\% \) (Analysis 2.2). Newsome 1988 found that there was more visual acuity loss in the control group than the treatment group although this did not reach statistical significance. Stur 1996 found little difference between the two groups with respect to mean visual acuity at the end of the study.

In Stur 1996 the primary outcome was incidence of choroidal neovascularisation (CNV) in all patients. During the treatment period, a CNV developed in the study eye in 14 patients (nine in the treatment group, five in the placebo group). People who experienced a CNV were not included in the analyses of visual acuity.
Outcome 3 progression AMD: dichotomous
Three trials provided data for this outcome (AREDS; Holz 1993; Stur 1996). A total of 969 people were randomised to zinc supplementation and 974 to placebo. Overall, there was a modest benefit of treatment (Analysis 2.3). The pooled OR was 0.73 (95% CI 0.58 to 0.93). Stur 1996 had quite different results to the other two trials. Over the treatment period, nine people experienced a CNV in the study eye in the zinc group compared to five people in the placebo group. This may have been a chance finding, however. The OR for that trial (2.31) had wide confidence intervals and the results are therefore also consistent with a protective effect of treatment (95% CI 0.58 to 9.26). Overall, the I² value was 29.0%. Holz 1993 has been published in abstract form only so we have little information about this trial.

Comparison 3: any multivitamin or single component antioxidant supplement versus placebo

Outcome 1, distance visual acuity: loss of 15 or more letters
Three trials contributed to this analysis (AREDS; Newsome 1988; VECA T). The trials were reasonably consistent (I² = 27.7%) (Analysis 3.1). Overall there was a small beneficial effect of supplementation (pooled OR fixed-effect model 0.81, 95% CI 0.67 to 0.98, P = 0.03). A random-effects model gave a different result (pooled OR 0.83, 95% CI 0.63 to 1.09, P = 0.18). The difference in these two models reflects the difference in weighting given to the largest trial (AREDS) - 75% in the fixed-effect model versus 63% in the random-effects model.

Outcome 2, distance visual acuity: mean
Not all trials reported visual acuity data in a dichotomous format. Some trials reported average distance visual acuity at the end of the follow-up period or the mean change in visual acuity. Five trials contributed to this analysis (AMDSG; Kaiser 1995; Newsome 1988; Stur 1996; Veterans LAST study). A total of 146 people were randomised to treatment and 140 to control. The results of the different studies were consistent (I² = 0%) (Analysis 3.2). There was little evidence of any benefit of treatment. The pooled standardised mean difference (random-effects model) was 0.02 (95% CI -0.21 to 0.26). A fixed-effect model gave identical results. Duration of treatment and follow up in these trials ranged from 6 to 24 months.

Outcome 3, progression AMD: dichotomous
Data on the progression of AMD was not reported or was reported in such a way as to make it difficult to extract data for this review in three studies (Kaiser 1995; Newsome 1988; Veterans LAST study).

Outcome 4, progression AMD: continuous
One study (AMDSG) reported data on the progression of AMD in a continuous format. There was little evidence for any benefit of treatment (mean difference -0.06, 95% CI -0.62 to 0.50). The number of participants in this analysis was small with 35 in the treatment group and 24 in the control group. There was limited information from the Chinese trial (Wang 2004), particularly about the definitions of the outcome. However, the authors reported that supplementation with zinc, vitamin E and vitamin C over 24 months had no effect on the progression of early ARM (chi-squared test P > 0.05) but had a beneficial effect on the progression of the disease in people with advanced AMD. 12/124 people receiving supplements who had large drusen, geographic atrophy or neovascularisation in one eye progressed to “advanced AMD” (not defined but perhaps comparable to the AREDS definitions) compared to 36/124 in the placebo group (chi-squared P < 0.05).

Comparison 4: Vitamin E versus placebo
There has only been one trial investigating vitamin E alone (VECAT). This trial randomised 587 participants to vitamin E supplementation and 592 to placebo and followed them up for four years on average.

Outcome 1 distance visual acuity: loss of three or more lines

Outcome 2 progression of AMD
There was no evidence of any effect of treatment either on visual acuity (OR 1.05, 95% CI 0.70 to 1.57) or progression of AMD (OR 1.11, 95% CI 0.80 to 1.55). Over 80% of participants in this trial did not have signs of ARM or AMD.

Comparison 5: lutein or zeaxanthin versus placebo

Outcome 1 distance visual acuity: mean

Outcome 2 progression of AMD
There has only been one trial published to date comparing supplementation with lutein versus placebo (Veterans LAST study). The trial was small with a total of 25 people randomised to lutein...
supplementation and 27 to placebo; the treatment duration and follow up was 12 months. The only outcome of relevance to this review, for which data could be extracted, was mean visual acuity at the end of the study. This showed little evidence of any effect of treatment: mean difference logMAR acuity 0.04 (95% CI -0.15 to 0.23). The power of the study was low.

Quality of life
None of the trials have reported on quality of life.

Adverse effects
The main reported adverse effect leading to withdrawal from the studies was gastrointestinal symptoms. Of 286 people randomised into trials of zinc sulfate supplementation compared to placebo, 5/146 zinc-treated people withdrew due to gastrointestinal symptoms compared to 2/140 controls. No-one developed copper-deficiency anaemia.

In AMDSG one person developed an ‘allergic reaction’ although it was not clear whether or not this was related to the treatment. AREDS considered a number of safety outcomes. They conducted over 100 comparisons of zinc versus no zinc and antioxidants versus no antioxidants. Participants in the antioxidant arms more frequently reported yellow skin (8.3% versus 6.0%, P = 0.008). Participants in the zinc arms reported more anaemia (13.2% versus 10.2%, P = 0.004), however, serum haematocrit levels were the same. They found that participants taking zinc had a lower mortality. Later follow-up of the cohort of people taking part in the AREDS study found that there was a significant increase in hospital admissions due to genitourinary diseases in people taking zinc supplements (11.1% versus 7.6% P = 0.0003) (Johnson 2007).

DISCUSSION
The trials contributing to this review fall into two categories. There are two large trials with reasonably long treatment duration and follow up of four to six years (AREDS; VECA T). The other six trials are smaller (ranging from 20 to 151 participants) and have shorter duration of treatment and follow up (6 to 24 months).

The large trials provide reasonably clear answers to different questions. The AREDS trial provides evidence that long-term supplementation with vitamins C, E, beta-carotene and zinc, in people with AMD, reduced the risk of progression of the disease and visual acuity loss. The overall benefit is modest with a risk reduction in the order of 20% to 25%. However, given that treatment options for AMD are limited, and vision loss is rarely recovered, this is of interest to people with AMD.

The VECA T study suggests that the general population should not take vitamin E with a view to preventing the incidence or progression of AMD. However, the study was underpowered to answer the question as to whether people with signs of AMD, such as those participating in the AREDS study, should take vitamin E. Currently VECA T is the only published trial on vitamin E supplementation and AMD.

The other trials of multivitamin preparations, Ocuguard (AMDSG), Ocupower (Veterans LAST study) and Visaline (Kaiser 1995) are too small to provide evidence either way. Pooling results, where possible, did not provide evidence of any benefit of supplementation. However, these trials were of relatively short duration.

A total of five trials investigated zinc supplementation (AREDS; France 1998; Holz 1993; Newsome 1988; Stur 1996). The AREDS study indicated that the beneficial effect of zinc supplementation was of a similar order to that of vitamin supplementation. The other trials provide more conflicting evidence. Newsome 1988 found a reduction in the risk of visual acuity loss with supplementation over 12 to 24 months. However, Stur 1996 found no effect of treatment. Unfortunately Stur 1996, which was planned to recruit 500 participants, was terminated early because the results of the first 40 patients at 24 months indicated no benefit of treatment. The other two trials of zinc supplementation are as yet unpublished, although limited results from Holz 1993 were published in abstract form and are included here. The trialists have been contacted with a view to including unpublished data in future versions of this review.

The main evidence that antioxidant vitamin and mineral supplementation is of benefit comes from the AREDS trial. As AREDS is a large well-conducted randomised study, potential biases will have been minimised. The only area where bias may have been introduced is if there were different systemic effects of the antioxidant and zinc supplementation (for example, yellowing of skin or difficulty swallowing tablets) which led the participants to guess which group they were in or alternatively, the retinal fundus photographs might have been different in some way such that the graders response was affected by treatment group. There is little evidence that this was a problem in the study.

AREDS was the only study to examine in detail the question of safety. They found little evidence of harm, however, recent follow-up of the cohort suggests an increased risk of hospital admission due to genitourinary complications in people taking the zinc supplements. The safety of some of the components of the AREDS formulation have been questioned in other studies. Two large randomised controlled trials have indicated that smokers who take beta-carotene may be at increased risk of developing lung cancer (ATBC; Omenn 1996). The Heart Outcomes Prevention Evaluation (HOPE) Study found that, among people with vascular disease or diabetes, vitamin E supplementation was associated with a higher risk of heart failure (Hope 2005).
AUTHORS’ CONCLUSIONS

Implications for practice

People with AMD may experience modest delay in progression of the disease with antioxidant vitamin and mineral supplementation. This finding is drawn from one large trial conducted in a relatively well-nourished American population. Until it is replicated by other large-scale trials in other populations we will not know whether these findings can be applied more generally.

Antioxidant vitamin and mineral supplements are readily available for purchase without prescription in many countries. The decision as to whether to take these supplements is at the discretion of the person with AMD. The following benefits and harms need to be considered. People with AMD may delay the progression of their condition if they take antioxidant vitamins and zinc at the levels described in this review. Given that there are few other interventions that offer much in the way of disease prevention or cure this is an important consideration. However, harmful effects associated with long-term vitamin supplementation, particularly in smokers and people with vascular disease, cannot be ruled out. A healthy diet with a variety of fresh fruit and vegetables will have many benefits and is unlikely to be harmful. It may be difficult, however, to consume as part of a normal diet the levels of antioxidants and zinc described in the trials included in this review. For example, one orange provides 80 mg of vitamin C; this is a relatively high amount. However, one would need to eat six to seven oranges daily to obtain 500 mg vitamin C.

There is currently considerable interest in the potential role of lutein and zeaxanthin supplementation in AMD. This review includes only one small equivocal trial on lutein. Such supplements currently cannot be recommended.

Implications for research

Trials in other populations, preferably with a variety of nutritional status, are required. These trials should have a large enough sample size to demonstrate effects that are meaningful for people and should also include a component on quality of life. It is likely that AMD develops over many years. Three categories of people may be identified: healthy people at risk because of age or genetic factors; people with early stages of the disease; people with intermediate or late-stage disease. There are likely to be differences in the potential protective effect of antioxidant supplementation depending on the stage of the disease.

ACKNOWLEDGEMENTS

I am grateful to:

- Michael Stur and Hedwig J Kaiser for helpful information about the zinc sulfate trial in Austria and the Visaline trial in Switzerland respectively;
- Roy Milton and the AREDS Coordinating Center for sending further information and unpublished data;
- everyone who responded to queries about trials of AMD;
- the Systematic Review Training Centre at Institute of Child Health, University College London for advice on protocol, and Steve Milan (Cochrane Airways Group) for advice on statistics;
- Ellen Schwartz for reading articles published in German;
- Maoling Wei from the Chinese Cochrane Centre for translating a report written in Chinese;
- Astrid Fletcher for peer review comments on the current version of this review and Argye Hillis for peer review comments on an earlier version of this review.

The Cochrane Eyes and Vision Group editorial team prepared and executed the electronic searches. Catey Bunce gave statistical advice.

REFERENCES

References to studies included in this review

AMDSG {published data only}


AREDS {published data only}


Clemons TE, Kurinji N, Sperduto RD, AREDS Research
Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration (Review)

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.


Kaiser 1993 [published data only]

Kaiser 1995 [published and unpublished data]

Newsome 1988 [published data only]

Stur 1996 [published data only]

VECAT [unpublished data only]

Veterans LAST study [published data only]


Wang 2004 [published data only]

References to studies excluded from this review

Bahrami 2006 [published data only]

Barakat 2006 [published data only]

Benzie 2006 [published data only]

Bone 2007 [published data only]

Cangemi 2007 [published data only]
Cangemi FE, TOZAL. Study: an open case control study of an oral antioxidant and omega-3 supplement for dry AMD. BMC Ophthalmology 2007;7:3.

Christen 2007 [published data only]

Cumurcu 2006 [published data only]

Franciose 2006 [published data only]

Goodrow 2006 [published data only]
Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration (Review)

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Kamburoglu 2006 [published data only]

Khachik 2006 [published data only]

Kopsell 2006 [published data only]

Lim 2006 [published data only]

LUNA study [published data only]

LUXEA [published data only]


Moeller 2006 [published data only]

Nolan 2006 [published data only]

Nolan 2007 [published data only]

Nussenblatt 2006 [published data only]

Owsley 2006 [published data only]

Rosenthal 2006 [published data only]

Vannas 1958 [published data only]

Wang 2007 [published data only]

Wenzel 2006 [published data only]

Zhao 2006 [published data only]

References to studies awaiting assessment

France 1998 [unpublished data only]
Professor Soubrane. Zinc supplementation. Universitaire de Cretell, France.

Additional references

ARMSG 1995
The International ARM Epidemiological Study Group.
An international classification and grading system for age-related maculopathy.

**ATBC**

**Bressler 1989**

**Christen 1996**

**ETDRS 1980**

**Evans 1996**

**Evans 2008**

**Glanville 2006**

**Higgins 2006**

**Hope 2005**

**Johnson 2007**

**Klein 1991**

**Klein 1992**

**Omenn 1996**

* Indicates the major publication for the study.
## Characteristics of included studies  
### AMDSG

| Method of allocation: Sponsor prepared coded tablets. |
| Masking: Participant - not clear; Provider - yes; Outcome - yes. |
| Losses to follow up: 4 died (2 treatment, 2 control); 1 adverse effect withdrawn (treatment); 7 lost to follow up (1 treatment, 6 control) |

### Participants

| Country: USA. |
| Number of participants randomised: 71 veterans. |
| Age: Average age 72 years. |
| Sex: 66 male 5 female. |
| Inclusion criteria: People with a monocular one line drop in Snellen visual acuity not attributable to cataract, amblyopia, systemic or ophthalmic disease AND clinically observable drusen, RPE disruption and loss of macular reflex. |
| Exclusion criteria: Greater than one year use of vitamins; ex-prisoners of war, chronic alcoholics with tobacco/nutritional amblyopia or gastrointestinal absorption disorders |

### Interventions

| Treatment: Ocuguard (Twin Lab Inc, Ronkonkoma, NY) broad spectrum antioxidant: beta carotene 20,000 IU, vitamin E 200 IU, vitamin C 750 mg, citrus bioflavonoid complex 125 mg, quercitin (bioflavonoid) 50 mg, bilberry extract (bioflavonoid) 5 mg, rutin (bioflavonoid) 50 mg, zinc picolinate 12.5 mg, selenium 50 mcg, taurine 100 mg, n-acetyl cysteine 100mg, l-glutathione 5 mg, vitamin B2 25 mg, chromium 100 mcg. |
| Control: Starch placebo. |
| Duration: 18 months. |

### Outcomes

| Snellen acuity with best refraction converted to logMAR units for analysis; Near vision M units with dual sided Bailey-Lovie chart; Contrast sensitivity; Retinal grading score (adapted from Chesapeake Bay Study) ; Subjective perception of vision; Adverse gastrointestinal reactions |

### Notes

| Treatment and placebo may not have been identical. |
| Funders: Twin Laboratories Inc, Ronkokoma NY; Stereo Optical Inc, Chicago, IL; Eye Communications Inc, Upland, CA; Illinois College of Optometry, Chicago, IL; Pacific University College of Optometry, Forest Grove, OR; Ezell Foundation, American Academy of Optometry, Rockville, MD |

### Risk of bias

<table>
<thead>
<tr>
<th>Item</th>
<th>Authors’ judgement</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allocation concealment?</td>
<td>Yes</td>
<td>A - Adequate</td>
</tr>
</tbody>
</table>
### AREDS

**Methods**
- Method of allocation: Coded bottles.
- Masking: Participant - yes; Provider - yes; Outcome - yes.
- Losses to follow-up: 2.4% balanced across study groups.

**Participants**
- Country: USA.
- Number of participants randomised: 3640.
- Age: Average age 69 years (range 55 to 80).
- Sex: 56% female.
- Inclusion criteria: 20/32 or better in at least one eye; ocular media clear and therefore able to obtain adequate stereoscopic fundus photographs; at least one eye free from eye disease that could complicate assessment of AMD.
- Exclusion criteria: Illness or disorders that would make long term follow-up or compliance with study protocol unlikely or difficult.

**Interventions**
- Treatment: Antioxidants (500mg vitamin C, 400IU vitamin E, 15mg beta carotene) zinc (80mg of zinc as zinc oxide and 2mg of copper as cupric oxide).
- Control: Placebo identical in external appearance and similar in internal appearance and taste.
- Duration: 7 years.

**Outcomes**
- Primary outcomes: (1) progression to advanced AMD and (2) 15 letter or more decrease in visual acuity score. AMD assessed using stereoscopic fundus colour photographs; visual acuity measured using EDTRS logMAR chart. Safety outcomes included: reported adverse events; serum levels of haemoglobin; hospitalisations and mortality.

**Notes**
- 2x2 factorial design. 67% participants took additional supplements to RDA levels (Centrum). In 1996 current smokers offered option of discontinuing supplementation; 2% of participants and 18% of smokers did so. A further 2.3% reassigned to no beta-carotene group. Intention to treat analysis maintained.

### Risk of bias

<table>
<thead>
<tr>
<th>Item</th>
<th>Authors’ judgement</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allocation concealment?</td>
<td>Yes</td>
<td>A - Adequate</td>
</tr>
</tbody>
</table>

### Holz 1993

**Methods**
- Method of allocation: Not known.
- Masking: Participant - yes; Provider - yes; Outcome - yes.
- Losses to follow-up: Not known.

**Participants**
- Country: UK.
- Number of participants randomised: 58.
- Age: 55 - 82, mean 68.

**Interventions**
- Treatment: 100mg zinc sulfate twice daily.
- Control: Placebo.
- Duration: 12 to 24 months.
### Holz 1993 (Continued)

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Visual acuity; Contrast sensitivity; Dark adaptation; Stereo fundus photographs and fluorescein angiograms</th>
</tr>
</thead>
<tbody>
<tr>
<td>Notes</td>
<td>Data available from abstract only.</td>
</tr>
</tbody>
</table>

### Risk of bias

<table>
<thead>
<tr>
<th>Item</th>
<th>Authors' judgement</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allocation concealment?</td>
<td>Unclear</td>
<td>B - Unclear</td>
</tr>
</tbody>
</table>

### Kaiser 1995

**Methods**
- Method of allocation: Sponsor prepared coded tablets.
- Masking: Participant - yes; Provider - yes; Outcome - yes.
- Losses to follow-up: None.

**Participants**
- Country: Switzerland.
- Number of participants randomised: 20.
- Age: over 50. Average age 72 in treatment group, 74 in control group.
- Sex: 7 male, 20 female.
- Inclusion criteria: People with nonserous AMD. All participants had regional atrophy of the pigment epithelium.
- Corrected visual acuity was between 20/100 and 20/25 with distance correction of less than four dioptres.
- Exclusion criteria: People with diabetes mellitus, endocrine problems, cardiac dysrhythmia, cardiac infarction or hypotension, other ocular disorders.

**Interventions**
- Treatment: Visaline (Novopharma Cham, Switzerland). Each tablet contains 1.5mg buphenine HCl, 10 mg beta-carotene, 10 mg tocopherol acetate, and 50 mg ascorbic acid. Participants took 2 tablets in the morning and at night, daily except for Saturdays and Sundays.
- Control: Placebo resembling active treatment prepared by sponsor.
- Duration: 6 months.

**Outcomes**
- Only one eye per person was evaluated. In cases of bilateral AMD, the eye with better visual acuity was selected.
- Distance and near visual acuity; Intraocular pressure; Visual fields; Lens opacity; Retinal visual acuity; Colour vision; Contrast sensitivity

### Risk of bias

<table>
<thead>
<tr>
<th>Item</th>
<th>Authors' judgement</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allocation concealment?</td>
<td>Yes</td>
<td>A - Adequate</td>
</tr>
</tbody>
</table>
### Newsome 1988

<table>
<thead>
<tr>
<th>Method of allocation: Computer generated table of random numbers. Masking: Participant - yes; Provider - yes; Outcome - yes. Losses to follow up: 23 (10 treatment, 13 placebo).</th>
</tr>
</thead>
<tbody>
<tr>
<td>Participants: Country: USA. Number of participants randomised: 174. Age: 42 to 89. Sex: 61 men 113 women. Inclusion criteria: Macular degeneration: clinically visible drusen with varying degrees of pigmentary change with visual acuity in one eye of 20/80 or better. Exclusion criteria: Cataract reducing vision more than one line; other known serious eye disease; diabetes mellitus; other known systematic/metabolic disease or congenital condition which might interfere with results</td>
</tr>
<tr>
<td>Interventions: Treatment: Zinc sulfate 100mg twice daily. Control: Identical tablets with lactose and fructose. Duration: 1 to 2 years.</td>
</tr>
<tr>
<td>Outcomes: Pinhole corrected visual acuity using ETDRS charts; Changes in visible pigment, drusen or atrophy from grading of macular photographs; Adverse effects of zinc including copper deficiency anaemia</td>
</tr>
<tr>
<td>Notes: Funders: Research Fund, Department of Veterinary Science, Utah State University, Logan; James L Shupe, DVM; Mary Katherine Peterson Foundation, Houston</td>
</tr>
</tbody>
</table>

### Risk of bias

<table>
<thead>
<tr>
<th>Item</th>
<th>Authors’ judgement</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allocation concealment?</td>
<td>Yes</td>
<td>A - Adequate</td>
</tr>
</tbody>
</table>

### Stur 1996

<table>
<thead>
<tr>
<th>Method of allocation: sponsor prepared coded bottles. Masking: Participant - yes; Provider - yes; Outcome - yes. Losses to follow up: 6 withdrawn due to adverse gastrointestinal effects (4 treatment, 2 control); 14 withdrawn when developed neovascularisation (9 treatment, 5 control); 14 lost to follow up (6 treatment, 8 control)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Participants: Country: Austria. Number of participants randomised: 112. Age: 50 plus. Sex: 48 men, 64 women. Inclusion criteria: Exudative AMD in one eye (defined as angiographic evidence of classic or occult choroidal neovascularisation or RPE detachment) and early ARM with visual acuity 20/40 or better in other eye (early ARM: macular drusen with no angiographic evidence of exudative lesion). Exclusion criteria: Dense senile cataract; any other eye disease which could produce significant and permanent loss of visual acuity during follow up; physical status that could prevent follow up; history of serious systemic or metabolic disease</td>
</tr>
</tbody>
</table>

---

Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration (Review)  
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
### Interventions

**Treatment:** Zinc sulfate 200 mg once daily. Lemon flavoured effervescent tablet made of citric acid containing saccharine and sorbitol.

**Control:** As treatment but without zinc sulfate.

**Duration:** 24 months.

### Outcomes

Best corrected LogMAR visual acuity measured using Bailey-Lovie chart; Contrast sensitivity; Incidence of choroidal neovascularisation; Progression of disease (Wisconsin Age-related Maculopathy Grading System); Copper deficiency anaemia

### Notes

A priori sample size estimate was 500 patients but trial stopped early because interim analysis showed no detectable trend.

**Funders:** Astra, Linz, Austria; Austrian Foundation for the Propagation of Scientific Research

### Risk of bias

<table>
<thead>
<tr>
<th>Item</th>
<th>Authors’ judgement</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allocation concealment?</td>
<td>Yes</td>
<td>A - Adequate</td>
</tr>
</tbody>
</table>

### VECAT

**Methods**

Method of allocation: Coded bottles.

Masking: Participant - yes; Provider - yes; Outcome - yes.

Losses to follow up: Not known.

**Participants**

Country: Australia.

Number of participants randomised: 1204.

Age: 55 - 80 mean 66.

Sex: 56% female.

Inclusion criteria: Lens and retina of at least one eye available for documentation.

Exclusion criteria: Previous cataract surgery or advanced cataract in both eyes; steroid or anticoagulation use; serious disease; regular use or sensitivity to vitamin E.

**Interventions**

Vitamin E 500 IU per day; natural vitamin E in soybean oil medium.

Control: Placebo identical in sight, taste and smell.

Duration: 4 years.

**Outcomes**

2m logMAR visual acuity; clinical examination; colour stereoscopic fundus photographs graded using International Grading Scheme

**Notes**

Worse eye used as the study eye.

Methodology published but results available from abstract only

### Risk of bias

<table>
<thead>
<tr>
<th>Item</th>
<th>Authors’ judgement</th>
<th>Description</th>
</tr>
</thead>
</table>
VECAT  (Continued)

<table>
<thead>
<tr>
<th>Allocation concealment?</th>
<th>Yes</th>
<th>A - Adequate</th>
</tr>
</thead>
</table>

**Veterans LAST study**

**Methods**
- Method of allocation: Coded bottles.
- Masking: Participant - yes; Provider - yes; Outcome - yes.
- Losses to follow up: 7 withdrew, 4 lost to follow-up, 3 died. Slightly lower % follow up in group 2 (lutein/antioxidant) 80% compared to other 2 group (lutein alone 86% placebo 87%)

**Participants**
- Country: USA.
- Number of participants randomised: 90.
- Approximate average age 75 years.
- Sex: 86/90 male.
- Inclusion criteria: Atrophic AMD diagnosed by ophthalmoscopy and at least one visual abnormality: reduced contrast sensitivity, photo-stress glare recovery deficit or deficit on Amsler grid. Clear ocular media, free of any other ocular/systemic disease that could affect central or parafoveal macular visual function.
- Exclusion criteria: Cataract or retinal surgery within 6 months, photosensitizing drugs, taken lutein supplements within the previous six months

**Interventions**
- Treatment: Group 1 L: Lutein 10mg non-esterified lutein (FloraGlo from Kemin Foods International, Des Moines, Iowa); Group 2 L/A: Lutein plus additional antioxidants and nutrients (OcuPower (see below) from Nutraceutical Sciences Institute (NSI), Boynton Beach, Florida) Group 3 P: maltodextrin.
- Duration: 12 months
- Ocupower had a range of nutrients including lutein, vitamin A, betacarotene, vitamins C, D3, E, B1, B2, B3, B5, B6, B12, folic acid, biotin, calcium, magnesium, iodine, zinc copper, manganese, selenium, chromium, molybdenum, lycopene, bilberry extract, alpha lipoic acid, N-acetyl cysteine, quercetin, rutin, citrus bioflavonoids, plant enzymes, black pepper extract, malic acid, taurine, L-glycine, L-glutathione, boron

**Outcomes**
- The following clinical measurements were made: Lens opacity; retinal images; Macular Pigment Optical Density (MPOD); visual acuity (Snellen) distance and near; glare testing; glare recovery; contrast sensitivity; VFQ-14 (activities of daily living, night driving, glare recovery symptoms); Amsler grid; self-reported vision

**Notes**
- It was difficult to extract data on outcomes of relevance to this review: i.e. visual acuity and progression of AMD

**Risk of bias**

<table>
<thead>
<tr>
<th>Item</th>
<th>Authors’ judgement</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allocation concealment?</td>
<td>Yes</td>
<td>A - Adequate</td>
</tr>
</tbody>
</table>
Wang 2004

Methods
Method of allocation: Unknown.
Masking: Participant - unknown; Provider - unknown; Outcome - unknown.
Losses to follow up: unknown

Participants
Country: China
Number of participants randomised: 400
188 men / 212 women aged 52 to 76, average age 65

Interventions
Treatment: zinc oxide 80mg daily, vitamin C, vitamin E. Control: placebo
Duration 24 to 32 months.

Outcomes
Outcomes: visual acuity

Notes
Limited information available on this trial. AMD patients were stratified in early and late stage disease

Risk of bias

<table>
<thead>
<tr>
<th>Item</th>
<th>Authors’ judgement</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allocation concealment?</td>
<td>Unclear</td>
<td>B - Unclear</td>
</tr>
</tbody>
</table>

AMD: age-related macular degeneration
ETDRS: Early Treatment Diabetic Retinopathy Study
RPE: retinal pigment epithelium
MPOD: macular pigment optical density

Characteristics of excluded studies  [ordered by study ID]

<table>
<thead>
<tr>
<th>Study</th>
<th>Reason for exclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bahrami 2006</td>
<td>Not AMD.</td>
</tr>
<tr>
<td>Barakat 2006</td>
<td>Not antioxidant vitamin.</td>
</tr>
<tr>
<td>Benzie 2006</td>
<td>Bioavailability study</td>
</tr>
<tr>
<td>Bone 2007</td>
<td>Bioavailability study.</td>
</tr>
<tr>
<td>Cangemi 2007</td>
<td>No control group.</td>
</tr>
<tr>
<td>Christen 2007</td>
<td>RCT in healthy population group. Included in Cochrane review on prevention of AMD with antioxidant supplements</td>
</tr>
<tr>
<td>Cumurcu 2006</td>
<td>Not RCT.</td>
</tr>
</tbody>
</table>
Franciose 2006  Bioavailability study.
Goodrow 2006  Bioavailability study.
Kamburoglu 2006  Not RCT, not antioxidant
Khachik 2006  Bioavailability study.
Kopsell 2006  Bioavailability study.
Lim 2006  Not antioxidant
LUNA study  Bioavailability study.
LUXEA  MPOD only measured; no clinical outcomes.
Moeller 2006  Not RCT.
Nolan 2006  Not RCT.
Nolan 2007  Not RCT.
Nussenblatt 2006  Not AMD.
Owsley 2006  Not antioxidant.
Rosenthal 2006  Small dose ranging study. Data on vision only collected for nine months and not possible to extract from report
Vannas 1958  Allocation concealment inadequate.
Wang 2007  Bioavailability study.
Wenzel 2006  Bioavailability study.
Zhao 2006  Bioavailability study.

AMD: age-related macular degeneration
MPOD: macular pigment optical density
RCT: randomised controlled trial
## DATA AND ANALYSES

**Comparison 1. Multivitamin supplement versus placebo**

<table>
<thead>
<tr>
<th>Outcome or subgroup title</th>
<th>No. of studies</th>
<th>No. of participants</th>
<th>Statistical method</th>
<th>Effect size</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Distance visual acuity: mean</td>
<td>3</td>
<td>131</td>
<td>Std. Mean Difference (IV, Fixed, 95% CI)</td>
<td>0.16 [-0.19, 0.51]</td>
</tr>
<tr>
<td>1.1 Mean visual acuity at end of study</td>
<td>3</td>
<td>131</td>
<td>Std. Mean Difference (IV, Fixed, 95% CI)</td>
<td>0.16 [-0.19, 0.51]</td>
</tr>
</tbody>
</table>

**Comparison 2. Zinc versus placebo**

<table>
<thead>
<tr>
<th>Outcome or subgroup title</th>
<th>No. of studies</th>
<th>No. of participants</th>
<th>Statistical method</th>
<th>Effect size</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Distance visual acuity: loss of 3 or more lines</td>
<td>2</td>
<td>1958</td>
<td>Odds ratio (Fixed, 95% CI)</td>
<td>0.81 [0.66, 0.99]</td>
</tr>
<tr>
<td>2 Distance visual acuity: mean</td>
<td>2</td>
<td>286</td>
<td>Std. Mean Difference (IV, Fixed, 95% CI)</td>
<td>Totals not selected</td>
</tr>
<tr>
<td>2.1 Mean visual acuity at end of study</td>
<td>1</td>
<td>157</td>
<td>Std. Mean Difference (IV, Fixed, 95% CI)</td>
<td>Not estimable</td>
</tr>
<tr>
<td>2.2 Change in visual acuity</td>
<td>1</td>
<td>129</td>
<td>Std. Mean Difference (IV, Fixed, 95% CI)</td>
<td>Not estimable</td>
</tr>
<tr>
<td>3 Progression AMD: dichotomous</td>
<td>3</td>
<td>1943</td>
<td>Odds ratio (Fixed, 95% CI)</td>
<td>0.73 [0.58, 0.93]</td>
</tr>
</tbody>
</table>

**Comparison 3. Any multivitamin or single component antioxidant supplement versus placebo**

<table>
<thead>
<tr>
<th>Outcome or subgroup title</th>
<th>No. of studies</th>
<th>No. of participants</th>
<th>Statistical method</th>
<th>Effect size</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Distance visual acuity: loss of 3 or more lines</td>
<td>3</td>
<td>4970</td>
<td>Odds ratio (Fixed, 95% CI)</td>
<td>0.81 [0.67, 0.98]</td>
</tr>
<tr>
<td>2 Distance visual acuity: mean</td>
<td>5</td>
<td>286</td>
<td>Std. Mean Difference (IV, Random, 95% CI)</td>
<td>0.02 [-0.21, 0.26]</td>
</tr>
<tr>
<td>2.1 Mean visual acuity at end of study</td>
<td>3</td>
<td>157</td>
<td>Std. Mean Difference (IV, Random, 95% CI)</td>
<td>0.11 [-0.21, 0.42]</td>
</tr>
<tr>
<td>2.2 Change in visual acuity</td>
<td>2</td>
<td>129</td>
<td>Std. Mean Difference (IV, Random, 95% CI)</td>
<td>-0.04 [-0.66, 0.59]</td>
</tr>
<tr>
<td>3 Progression AMD: dichotomous</td>
<td>4</td>
<td>1942</td>
<td>Odds ratio (Random, 95% CI)</td>
<td>Totals not selected</td>
</tr>
</tbody>
</table>
### Analysis 1.1. Comparison 1 Multivitamin supplement versus placebo, Outcome 1 Distance visual acuity: mean.

Review: Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration

Comparison: 1 Multivitamin supplement versus placebo

Outcome: 1 Distance visual acuity: mean

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Antioxidant</th>
<th>Placebo</th>
<th>Std. Mean Difference</th>
<th>Weight</th>
<th>Std. Mean Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMDSG</td>
<td>35</td>
<td>24</td>
<td>0.11 [-0.41, 0.63]</td>
<td>44.4%</td>
<td></td>
</tr>
<tr>
<td>Kaiser 1995</td>
<td>9</td>
<td>11</td>
<td>-0.07 [-0.95, 0.81]</td>
<td>15.5%</td>
<td></td>
</tr>
<tr>
<td>Veterans LAST study</td>
<td>25</td>
<td>27</td>
<td>0.30 [-0.24, 0.85]</td>
<td>40.1%</td>
<td></td>
</tr>
<tr>
<td><strong>Total (95% CI)</strong></td>
<td><strong>69</strong></td>
<td><strong>62</strong></td>
<td>0.16 [-0.19, 0.51]</td>
<td>100.0%</td>
<td></td>
</tr>
</tbody>
</table>

Heterogeneity: Chi$^2$ = 0.56, df = 2 (P = 0.76); I$^2$ = 0.0%
Test for overall effect: Z = 0.91 (P = 0.36)
Test for subgroup differences: Not applicable

### Analysis 2.1. Comparison 2 Zinc versus placebo, Outcome 1 Distance visual acuity: loss of 3 or more lines.

Review: Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration

Comparison: 2 Zinc versus placebo

Outcome: 1 Distance visual acuity: loss of 3 or more lines

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Zinc</th>
<th>Placebo</th>
<th>log [Odds ratio] (SE)</th>
<th>Odds ratio</th>
<th>Weight</th>
<th>Odds ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>AREDS</td>
<td>904</td>
<td>903</td>
<td>-0.1985 (0.1045)</td>
<td>0.82 [0.67, 1.01]</td>
<td>97.2%</td>
<td></td>
</tr>
<tr>
<td>Newsome 1988</td>
<td>80</td>
<td>71</td>
<td>-0.8159 (0.6123)</td>
<td>0.44 [0.13, 1.47]</td>
<td>2.8%</td>
<td></td>
</tr>
<tr>
<td><strong>Total (95% CI)</strong></td>
<td><strong>100.0%</strong></td>
<td><strong>100.0%</strong></td>
<td><strong>0.81 [0.66, 0.99]</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Heterogeneity: Chi$^2$ = 0.99, df = 1 (P = 0.32); I$^2$ = 0.0%
Test for overall effect: Z = 2.10 (P = 0.036)
Test for subgroup differences: Not applicable
Analysis 2.2. Comparison 2 Zinc versus placebo, Outcome 2 Distance visual acuity: mean.

Review: Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration

Comparison: 2 Zinc versus placebo

Outcome: 2 Distance visual acuity: mean

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Zinc</th>
<th>Placebo</th>
<th>Std. Mean Difference</th>
<th>Std. Mean Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N Mean(SD)</td>
<td>N Mean(SD)</td>
<td>IV,Fixed,95% CI</td>
<td>IV,Fixed,95% CI</td>
</tr>
<tr>
<td>1 Mean visual acuity at end of study</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stur 1996</td>
<td>37 0.05 (0.12)</td>
<td>41 0.03 (0.14)</td>
<td>0.15 [-0.29, 0.60]</td>
<td></td>
</tr>
<tr>
<td>2 Change in visual acuity</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Newsome 1988</td>
<td>40 0.08 (0.12)</td>
<td>37 0.14 (0.22)</td>
<td>-0.34 [-0.79, 0.11]</td>
<td></td>
</tr>
</tbody>
</table>
### Analysis 2.3. Comparison 2 Zinc versus placebo, Outcome 3 Progression AMD: dichotomous.

Review: Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration

Comparison: 2 Zinc versus placebo

Outcome: 3 Progression AMD: dichotomous

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Zinc</th>
<th>Placebo</th>
<th>log [Odds ratio]</th>
<th>Odds ratio</th>
<th>Weight</th>
<th>Odds ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>N</td>
<td>(SE)</td>
<td>IV,Fixed,95% CI</td>
<td></td>
<td>IV,Fixed,95% CI</td>
</tr>
<tr>
<td>AREDS</td>
<td>904</td>
<td>903</td>
<td>-0.3425 (0.1266)</td>
<td>95.8 %</td>
<td>0.71 [0.55, 0.91]</td>
<td></td>
</tr>
<tr>
<td>Holz 1993</td>
<td>28</td>
<td>30</td>
<td>-0.6931 (1.1533)</td>
<td>1.2 %</td>
<td>0.50 [0.05, 4.79]</td>
<td></td>
</tr>
<tr>
<td>Stur 1996</td>
<td>37</td>
<td>41</td>
<td>0.8391 (0.7073)</td>
<td>3.1 %</td>
<td>2.31 [0.58, 9.26]</td>
<td></td>
</tr>
<tr>
<td><strong>Total (95% CI)</strong></td>
<td></td>
<td></td>
<td></td>
<td>100.0 %</td>
<td>0.73 [0.58, 0.93]</td>
<td></td>
</tr>
</tbody>
</table>

Heterogeneity: $\chi^2 = 2.82$, df = 2 ($P = 0.24$); $I^2 = 29\%$

Test for overall effect: $Z = 2.50$ ($P = 0.012$)

Test for subgroup differences: Not applicable

### Analysis 3.1. Comparison 3 Any multivitamin or single component antioxidant supplement versus placebo, Outcome 1 Distance visual acuity: loss of 3 or more lines.

Review: Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration

Comparison: 3 Any multivitamin or single component antioxidant supplement versus placebo

Outcome: 1 Distance visual acuity: loss of 3 or more lines

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Antioxidant</th>
<th>Placebo</th>
<th>log [Odds ratio]</th>
<th>Odds ratio</th>
<th>Weight</th>
<th>Odds ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>N</td>
<td>(SE)</td>
<td>IV,Fixed,95% CI</td>
<td></td>
<td>IV,Fixed,95% CI</td>
</tr>
<tr>
<td>AREDS</td>
<td>2737</td>
<td>903</td>
<td>-0.2614 (0.1113)</td>
<td>75.4 %</td>
<td>0.77 [0.62, 0.96]</td>
<td></td>
</tr>
<tr>
<td>Newsome 1988</td>
<td>80</td>
<td>71</td>
<td>-0.8159 (0.6123)</td>
<td>2.5 %</td>
<td>0.44 [0.13, 1.47]</td>
<td></td>
</tr>
<tr>
<td>VECAT</td>
<td>587</td>
<td>592</td>
<td>0.0477 (0.2053)</td>
<td>22.1 %</td>
<td>1.05 [0.70, 1.57]</td>
<td></td>
</tr>
<tr>
<td><strong>Total (95% CI)</strong></td>
<td></td>
<td></td>
<td></td>
<td>100.0 %</td>
<td>0.81 [0.67, 0.98]</td>
<td></td>
</tr>
</tbody>
</table>

Heterogeneity: $\chi^2 = 2.77$, df = 2 ($P = 0.25$); $I^2 = 28\%$

Test for overall effect: $Z = 2.14$ ($P = 0.032$)

Test for subgroup differences: Not applicable
### Analysis 3.2. Comparison 3 Any multivitamin or single component antioxidant supplement versus placebo, Outcome 2 Distance visual acuity: mean.

Review: Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration

Comparison: 3 Any multivitamin or single component antioxidant supplement versus placebo

Outcome: 2 Distance visual acuity: mean

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Antioxidant</th>
<th>Placebo</th>
<th>Std. Mean Difference</th>
<th>Weight</th>
<th>Std. Mean Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N Mean(SD)</td>
<td>N Mean(SD)</td>
<td>IV, Random, 95% CI</td>
<td></td>
<td>IV, Random, 95% CI</td>
</tr>
<tr>
<td>AMDSG</td>
<td>35 0.33 (0.41)</td>
<td>24 0.29 (0.24)</td>
<td>20.2 %</td>
<td>0.11 [-0.41, 0.63]</td>
<td></td>
</tr>
<tr>
<td>Kaiser 1995</td>
<td>9 0.17 (0.7)</td>
<td>11 0.22 (0.66)</td>
<td>7.0 %</td>
<td>-0.07 [-0.95, 0.81]</td>
<td></td>
</tr>
<tr>
<td>Stur 1996</td>
<td>37 0.05 (0.12)</td>
<td>41 0.03 (0.14)</td>
<td>27.6 %</td>
<td>0.15 [-0.29, 0.60]</td>
<td></td>
</tr>
<tr>
<td><strong>Subtotal (95% CI)</strong></td>
<td><strong>81</strong></td>
<td><strong>76</strong></td>
<td><strong>54.8 %</strong></td>
<td><strong>0.11 [-0.21, 0.42]</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Heterogeneity:</strong></td>
<td>Tau² = 0.0; Chi² = 0.19, df = 2 (P = 0.91); I² =0.0%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Test for overall effect:</strong></td>
<td>Z = 0.67 (P = 0.50)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Parkinson 1988</td>
<td>40 0.08 (0.12)</td>
<td>37 0.14 (0.22)</td>
<td>26.9 %</td>
<td>-0.34 [-0.79, 0.11]</td>
<td></td>
</tr>
<tr>
<td>Veterans LAST study</td>
<td>25 -0.03 (0.25)</td>
<td>27 -0.14 (0.44)</td>
<td>18.2 %</td>
<td>0.30 [-0.25, 0.85]</td>
<td></td>
</tr>
<tr>
<td><strong>Subtotal (95% CI)</strong></td>
<td><strong>65</strong></td>
<td><strong>64</strong></td>
<td><strong>45.2 %</strong></td>
<td><strong>-0.04 [-0.66, 0.59]</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Heterogeneity:</strong></td>
<td>Tau² = 0.14; Chi² = 3.12, df = 1 (P = 0.08); I² =68%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Test for overall effect:</strong></td>
<td>Z = 0.12 (P = 0.90)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td><strong>146</strong></td>
<td><strong>140</strong></td>
<td><strong>100.0 %</strong></td>
<td><strong>0.02 [-0.21, 0.26]</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Heterogeneity:</strong></td>
<td>Tau² = 0.0; Chi² = 3.94, df = 4 (P = 0.41); I² =0.0%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Test for overall effect:</strong></td>
<td>Z = 0.19 (P = 0.85)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Analysis 3.3. Comparison 3 Any multivitamin or single component antioxidant supplement versus placebo, Outcome 3 Progression AMD: dichotomous.

Review: Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration

Comparison: Any multivitamin or single component antioxidant supplement versus placebo

Outcome: Progression AMD: dichotomous

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Antioxidant</th>
<th>Placebo</th>
<th>log [Odds ratio] (SE)</th>
<th>Odds ratio</th>
<th>Odds ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>N</td>
<td>IV, Random, 95% CI</td>
<td>IV, Random, 95% CI</td>
<td></td>
</tr>
<tr>
<td>AREDS</td>
<td>2737</td>
<td>903</td>
<td>0.3857 (0.1242)</td>
<td>0.68 [0.53, 0.87]</td>
<td></td>
</tr>
<tr>
<td>Holz 1993</td>
<td>28</td>
<td>30</td>
<td>0.6931 (1.1533)</td>
<td>0.50 [0.05, 4.79]</td>
<td></td>
</tr>
<tr>
<td>Stur 1996</td>
<td>37</td>
<td>41</td>
<td>0.8391 (0.7073)</td>
<td>2.31 [0.58, 9.26]</td>
<td></td>
</tr>
<tr>
<td>VECAT</td>
<td>587</td>
<td>592</td>
<td>0.1033 (0.1696)</td>
<td>1.11 [0.80, 1.55]</td>
<td></td>
</tr>
</tbody>
</table>

#### ADDITIONAL TABLES

Table 1. Supplementary information on trials

<table>
<thead>
<tr>
<th>Study</th>
<th>Type of AMD</th>
<th>Treatment</th>
<th>Treatment duration</th>
<th>Follow up</th>
<th>Visual acuity</th>
<th>Progression AMD</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMDSG</td>
<td>Early ARM</td>
<td>Ocuguard</td>
<td>18 months</td>
<td>18 months</td>
<td>Snellen converted to log-MAR: continuous score</td>
<td>Based on Chesapeake Bay grading but using indirect ophthalmoscopy: expressed as an average grade</td>
<td></td>
</tr>
<tr>
<td>AREDS</td>
<td>ARM &amp; VA 20/32 or better in one eye, 956/3640 had AMD.</td>
<td>Vitamin C, E, beta-carotene, zinc. Factorial design</td>
<td>Average duration 6.3 years</td>
<td>Average follow-up 6.3 years, 2.4% lost to follow up</td>
<td>Loss of 3 or more lines VA (equivalent to doubling visual angle)</td>
<td>Progression to advanced AMD: photocoagulation or other treatment for CNV; GA involving center of the macula,</td>
<td></td>
</tr>
<tr>
<td>Trial</td>
<td>Condition Descriptions</td>
<td>Treatment(s)</td>
<td>Follow-up Duration (months)</td>
<td>Outcome Measure</td>
<td>Notes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------------</td>
<td>----------------------------------------------------------------------------------------</td>
<td>--------------</td>
<td>-----------------------------</td>
<td>--------------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Holz 1993</td>
<td>People with drusen</td>
<td>Zinc</td>
<td>12-24</td>
<td>Incidence of new exudative or dry macula lesions</td>
<td>Not reported</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kaiser 1995</td>
<td>“Nonserous AMD”</td>
<td>Visaline</td>
<td>6</td>
<td>Average Snellen score reported, converted to logMAR for this review</td>
<td>Not reported</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Newsome 1988</td>
<td>Drusen and/or pigmentary change, VA 20/80 or better</td>
<td>Zinc</td>
<td>12-24</td>
<td>Number of letters lost on logMAR chart, converted to logMAR score for this review</td>
<td>Difficult to extract data on this. Reported number with increased pigment, drusen and atrophy for two observers. In general found results favouring the zinc treated group</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stur 1996</td>
<td>Neovascular AMD in one eye, VA better than 20/40 in other eye</td>
<td>Zinc</td>
<td>24</td>
<td>Mean logMAR score</td>
<td>Incidence of neovascular lesion in study eye</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>24</td>
<td>NOTE: patients with neovascular event excluded from this outcome</td>
<td>Original trial of n = 500 terminated by sponsor (Astra) because statistical evaluation of first 40 patients at 24 months follow up</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Table 1. Supplementary information on trials (Continued)

<table>
<thead>
<tr>
<th>Study</th>
<th>Early AMD (18%)</th>
<th>Late AMD (0.5%). Rest presumably had no signs of ARM</th>
<th>Vitamin E</th>
<th>48</th>
<th>48</th>
<th>Loss of more than 9 letters on logMAR chart (two lines)</th>
<th>Investigators defined six stages of AMD progression and defined progression as movement from a lower stage to a higher stage in their worst eye</th>
</tr>
</thead>
<tbody>
<tr>
<td>VEGAT</td>
<td>Early AMD (18%)</td>
<td>Late AMD (0.5%). Rest presumably had no signs of ARM</td>
<td>Vitamin E</td>
<td>48</td>
<td>48</td>
<td>Loss of more than 9 letters on logMAR chart (two lines)</td>
<td>Investigators defined six stages of AMD progression and defined progression as movement from a lower stage to a higher stage in their worst eye</td>
</tr>
<tr>
<td>Veterans study</td>
<td>Atrophic AMD and reduced vision</td>
<td>Lutein and/or Ocupower</td>
<td>12</td>
<td>12</td>
<td>Change in logMAR score</td>
<td>Data not reported</td>
<td></td>
</tr>
</tbody>
</table>

APPENDICES

Appendix 1. CENTRAL and NRR search strategies for Issue 3, 2007

#1 MeSH descriptor Macular Degeneration
#2 MeSH descriptor Retinal Degeneration
#3 MeSH descriptor Retinal Neovascularization
#4 MeSH descriptor Choroidal Neovascularization
#5 MeSH descriptor Macula Lutea
#6 macula* near lutea*
#7 ((macul* OR retina* OR choroid*:TI) AND (degener* OR neovasc*:TI))
#8 ((macul* OR retina* OR choroid*:AB) AND (degener* OR neovasc*:AB))
#9 maculopath*
#10 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9)
#11 MeSH descriptor Vitamins
#12 vitamin*
#13 MeSH descriptor Vitamin A
#14 retinol*
#15 MeSH descriptor beta Carotene
#16 caroten*
#17 MeSH descriptor Ascorbic Acid
#18 ascorbic next acid
#19 MeSH descriptor Vitamin E
Appendix 2. MEDLINE search strategy used on OVID up to August 2007

1. exp clinical trial/ [publication type]
2. (randomized or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
8. or/1-7
9. exp animals/
10. exp humans/
11. 9 not (9 and 10)
12. 8 not 11
13. exp macular degeneration/
14. exp retinal degeneration/
15. exp retinal neovascularization/
16. exp choroidal neovascularization/
17. exp macula lutea/
18. maculopathy$.tw.
19. ((macul$ or retina$ or choroid$) adj3 degener$).tw.
20. ((macul$ or retina$ or choroid$) adj3 neovasc$).tw.
22. or/13-21
23. exp vitamins/
24. exp vitamin A/
25. vitamin A.tw.
26. retinol$.tw.
The search filter for trials at the beginning of the MEDLINE strategy is from the published paper by Glanville (Glanville 2006).

Appendix 3. EMBASE search strategy used on OVID up to August 2007

We used the following strategy to search EMBASE on OVID to August 2007.
1. exp randomized controlled trial/
2. exp randomization/
3. exp double blind procedure/
4. exp single blind procedure/
5. random$.tw.
6. or/1-5
7. (animal or animal experiment).sh.
8. human.sh.
9. 7 and 8
10. 7 not 9
11. 6 not 10
12. exp clinical trial/
14. ((singl$ or doubl$ or trebl$ or tripl$) adj3 (blind$ or mask$)).tw.
15. exp placebo/
16. placebo$.tw.
Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration (Review)
Appendix 4. PubMed search strategy used on 24 January 2006 (last 60 days)

The following strategy was used to search PubMed.

#1 anti-oxidant* or antioxidant* or vitamin* or caroten*
#2 (beta next epsilon next caroten*) or beta-epsilon-caroten* or (alpha next tocopherol) or alpha-tocopherol or selenium or lutein* or zeaxanthin*
#3 (ascorbic next acid) or caroten* or beta-caroten* or betacaroten*
#4 #1 or #2 or #3
#5 macula* next lutea*
#6 (macul* or retina* or choroid*) and (degener* or neovasc*)
#7 AMD or maculopathy*
#8 #5 or #6 or #7
#9 #4 and #8

Appendix 5. AMED search strategy used up to January 2006

#1 anti-oxidant* or antioxidant* or vitamin* or caroten*
#2 (beta next epsilon next caroten*) or beta-epsilon-caroten* or (alpha next tocopherol) or alpha-tocopherol or selenium or lutein* or zeaxanthin*
#3 (ascorbic next acid) or caroten* or beta-caroten* or betacaroten*
#4 #1 or #2 or #3
#5 macula* next lutea*
#6 (macul* or retina* or choroid*) and (degener* or neovasc*)
#7 AMD or maculopathy*
#8 #5 or #6 or #7
#9 #4 and #8

Appendix 6. SIGLE search strategy used up to March 2005

#1 anti-oxidant* or antioxidant* or vitamin* or caroten*
#2 (beta next epsilon next caroten*) or beta-epsilon-caroten* or (alpha next tocopherol) or alpha-tocopherol or selenium or lutein* or zeaxanthin*
#3 (ascorbic next acid) or caroten* or beta-caroten* or betacaroten*
#4 #1 or #2 or #3
#5 macula* next lutea*
#6 (macul* or retina* or choroid*) and (degener* or neovasc*)
#7 AMD or maculopathy*
#8 #5 or #6 or #7
#9 #4 and #8
WHAT'S NEW

Last assessed as up-to-date: 1 August 2007.

<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>28 August 2008</td>
<td>Amended</td>
<td>Converted to new review format.</td>
</tr>
</tbody>
</table>

HISTORY

Review first published: Issue 1, 1998

<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>12 August 2007</td>
<td>New search has been performed</td>
<td>Issue 1 2008: Results of trial from China (Wang et al) added. Report from AREDS study on risk of hospital admission due to genitourinary complications in people taking high dose zinc. Graphs with only one trial have been deleted and results have been reported in the text</td>
</tr>
<tr>
<td>19 January 2006</td>
<td>New citation required and conclusions have changed</td>
<td>Substantive amendment</td>
</tr>
</tbody>
</table>

DECLARATIONS OF INTEREST

None known

SOURCES OF SUPPORT

Internal sources
- Moorfields Eye Hospital NHS Trust, UK.
External sources

- Guide Dogs for the Blind Association, UK.

NOTES

The Cochrane Eyes and Vision Group editorial team is aware that there has been some criticism of one trial included in this review (AREDS). We welcome comments and criticisms on the review through the feedback system of The Cochrane Library.

INDEX TERMS

Medical Subject Headings (MeSH)

*Dietary Supplements; Antioxidants [*therapeutic use]; Macular Degeneration [*prevention & control]; Minerals [*therapeutic use]; Randomized Controlled Trials as Topic; Vitamins [*therapeutic use]

MeSH check words

Aged; Humans